CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

The Revista Mexicana de Neurociencia, published by the ACAD MEXICANA NEUROLOGIA, serves as a pivotal platform for the dissemination of research within the field of neurology and neuroscience. Although it was active from 2008 to 2014 and is no longer covered in Scopus, the journal still holds a significant place in the academic community, addressing critical topics relevant to both clinical and experimental neurology. With an emphasis on advancing knowledge in neuropsychology and public health, this journal targets researchers, professionals, and students alike, fostering an interdisciplinary dialogue that can enhance the understanding of neurological conditions within Mexico and beyond. As it stands, the journal is not open access, which may present challenges for accessibility, yet its affiliation with recognized academic standards underlines its commitment to quality research. This platform once provided insights that can inform practice and stimulate innovative approaches in the management of neurological disorders, underscoring its importance in the evolving landscape of neuroscience.

Future Neurology, published by Future Medicine Ltd, is an emerging peer-reviewed journal dedicated to the rapidly evolving field of neurology, with a keen focus on both clinical and translational research. Since its inception in 2007, the journal has provided a unique platform for sharing innovative findings and fostering collaboration among neurologists, neuroscientists, and healthcare professionals. Although currently categorized in the Q4 quartile for both Neurology and Clinical Neurology, Future Neurology strives to improve its impact factor by publishing high-quality research and reviews that address pressing issues in neurological health. With its commitment to disseminating knowledge, the journal serves as an essential resource for professionals and researchers seeking to stay informed about advancements in neurological science. It is particularly valuable for those looking to contribute to and engage with the latest developments in neurotherapeutics, diagnostics, and patient care strategies. The journal is indexed in major databases and is available in print and online formats, ensuring wider accessibility to its content for all stakeholders in the field.

Nature Reviews Neurology, published by NATURE PORTFOLIO, stands as a leading scholarly journal dedicated to the field of neurology and neuroscience. With an impressive impact factor and a prestigious Q1 categorization in both Cellular and Molecular Neuroscience and Clinical Neurology, this journal provides cutting-edge reviews and insights into the latest research developments, trends, and clinical practices. Based in the United Kingdom and accessible to a global audience, Nature Reviews Neurology aims to foster knowledge dissemination and interdisciplinary collaboration among researchers, healthcare professionals, and educators. With an influential Scopus ranking, it remains a pivotal resource for those seeking to deepen their understanding of neurological disorders and therapies while remaining at the forefront of academic discourse and innovation in the field.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

Frontiers in Neurology is a premier open-access journal dedicated to the advancement of research in the field of neurology, published by FRONTIERS MEDIA SA since 2010. With the ISSN 1664-2295 and an international reach established from its base in Lausanne, Switzerland, this journal has rapidly become a vital resource for neurologists and neuroscientists alike, presenting high-quality research that addresses critical developments in clinical and experimental neurology. Holding a solid Q2 quartile ranking in both neurology and clinical neurology, Frontiers in Neurology demonstrates substantial influence, evidenced by its respectable Scopus rankings—151st in clinical neurology and 77th in neuroscience neurology. The journal employs robust peer review practices to ensure rigor and integrity, while its open-access model fosters widespread dissemination of knowledge. By facilitating interdisciplinary dialogue and empowering research efforts, this journal not only supports the academic community but also contributes to the advancement of treatment and understanding of neurological disorders.

Current Treatment Options in Neurology, published by CURRENT MEDICINE GROUP, is a pivotal journal in the field of clinical neurology, dedicated to enhancing the understanding and management of neurological disorders. With a print ISSN of 1092-8480 and an E-ISSN of 1534-3138, this journal serves as a vital resource for clinicians, researchers, and students alike, providing evidence-based insights and treatment strategies from its continuous publication since its inception in 1999. It currently holds a respectable rank in the Q3 quartile, reflecting its competitive standing in the Scopus rankings for clinical neurology, placing it at the 51st percentile. Although not classified as Open Access, the journal continues to provide valuable contributions that inform clinical practices and improve patient outcomes in neurological care. With its comprehensive reviews and clinical focus, Current Treatment Options in Neurology remains an essential platform for disseminating the latest advancements in treatment methodologies and therapeutic options, solidifying its importance in the ever-evolving landscape of neurology.